Bright Minds Biosciences Inc Stock Price, News & Analysis

Bright Minds Biosciences (NASDAQ: DRUG) announces two presentations at the American Epilepsy Society 2024 Annual Meeting in Los Angeles, December 6-10, 2024. The presentations will showcase data on BMB-101, their novel 5-HT2C agonist.

The first presentation by CSO Jan Torleif Pedersen will discuss Phase I study results on safety, tolerability, and pharmacokinetics of BMB-101. The second presentation by COO Alex Vasilkevich will focus on BMB-101's biased 5-HT2C agonism for epilepsy management. Both poster presentations are scheduled for Saturday, December 7, from 12:00 PM to 2:00 PM at South Hall H, Level 1.

Bright Minds Biosciences (CSE: DRUG) (NASDAQ: DRUG) has successfully closed a non-brokered private placement, raising USD$35 million through the issuance of 1,612,902 common shares at USD$21.70 per share. Notable participants include Cormorant Asset Management, RA Capital Management, Perceptive Advisors, and other healthcare investors. The proceeds will fund research and development programs and general working capital. The offering included insider participation from director Jeremy Fryzuk and Cormorant Asset Management, who collectively subscribed for 188,940 shares worth USD$4.1 million.

Bright Minds Biosciences (NASDAQ: DRUG) has announced a renewed collaboration with Firefly Neuroscience (NASDAQ: AIFF) for the analysis of EEG data from the BREAKTHROUGH study, a Phase 2 clinical trial of BMB-101. This open-label trial is evaluating the safety, tolerability, and efficacy of BMB-101, a selective 5-HT2C receptor agonist, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).

The study is designed as a basket clinical trial, targeting enrollment of 20 adult participants aged 18-65. It aims to address rare epilepsy disorders characterized by refractory seizures resistant to current treatments. Bright Minds believes BMB-101 has the potential to be a best-in-class 5-HT2C agonist with broad applicability across 30% of epilepsy patients experiencing drug resistance.

Bright Minds Biosciences (NASDAQ: DRUG) has announced positive preclinical data for its proprietary compound BMB-201, a 5-HT2C/2A mixed agonist. The study, conducted through the National Institute of Health pain screening program, demonstrated that BMB-201 had similar efficacy to morphine in several pain models, including plantar incision and L5/L6 nerve ligation in rats.

Key findings include:

• BMB-201 showed superior reductions in mechanical allodynia and pain-related behaviors compared to morphine in nerve ligation models
• Female rodents experienced significant improvement in pain relief and guarding behavior at higher doses
• The compound's efficacy suggests potential for better pain relief than traditional opioids without associated risks

Bright Minds plans to advance BMB-201 into clinical trials, aiming to position it as a non-opioid alternative for neuropathic pain relief.

At the request of CIRO, Bright Minds Biosciences (CSE: DRUG) (NASDAQ: DRUG) has confirmed that the company's management is unaware of any material changes in its operations that could explain the recent increase in market activity. This statement was made in response to unusual trading patterns observed in the company's stock.

The press release, dated October 15, 2024, serves as a formal declaration to investors and regulatory bodies that Bright Minds has not undergone any significant operational changes that would justify the recent market behavior. This type of announcement is often made to ensure transparency and compliance with stock exchange regulations.

Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for CNS disorders, announces participation in upcoming scientific conferences and partnering events. The company will present at:

• Neuroscience 2024 annual meeting in Chicago, October 5–9
• Therapeutic Development at NINDS Chicago, October 7
• BIO-Europe in Stockholm, November 4-6
• Chicago Biocapital Summit, November 6-7
• AES Annual Meeting 2024 in Los Angeles, December 6-10

Presentations will cover novel 5-HT2A-selective agonists, Phase I study results of BMB-101, and biased 5-HT2C agonism for epilepsy management. The company also granted 70,000 stock options to employees and board members, exercisable at $1.65 per share for five years, subject to vesting periods.

Bright Minds Biosciences (NASDAQ / CSE: DRUG) is hosting a Key Opinion Leader (KOL) event on September 25th, 2024, focusing on their Phase 2 BREAKTHROUGH clinical trial of BMB-101 for drug-resistant epilepsies. The event will feature renowned epilepsy experts Dr. Dennis Dlugos, Dr. Joe Sullivan, and Dr. Jo Sourbron, who will discuss unmet needs in epilepsy treatment and the potential of novel therapies.

BMB-101 is the first 5-HT2C agonist in clinical studies designed to target therapeutic pathways without receptor desensitization. The KOL event will provide insights into the evolving landscape of drug-resistant seizures and highlight the scientific innovations driving the trial design. Interested parties can register for the webcast in advance, with a replay available for those unable to attend live.

Bright Minds Biosciences (NASDAQ: DRUG) has initiated the BREAKTHROUGH Study, a Phase 2 clinical trial evaluating BMB-101, a selective 5-HT2C agonist, for Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE). The open-label trial aims to assess safety, tolerability, and efficacy in 20 adult patients aged 18-65. Key points include:

1. 4-week baseline period, followed by 8-12 week treatment phase and 4-week follow-up
2. Primary endpoints: change in generalized spike-wave discharges and seizure frequency
3. Planned open-label extension for responders
4. Financial runway extending into 2026
5. Investor call scheduled for September 25, 2024

The company believes BMB-101 has potential to be a best-in-class treatment for refractory epilepsy, addressing a significant unmet need.

Bright Minds Biosciences (CSE:DRUG, NASDAQ:DRUG) has received a positive Written Opinion from the International Searching Authority on its international patent application for phenethylamine compounds, which includes its lead clinical candidate BMB-202. This selective 5-HT_2A agonist shows over 30-fold selectivity against 5-HT_2C and over 500-fold against 5-HT_2B. The favorable report supports the company's strategy in drug discovery aimed at neuropsychiatric disorders, epilepsy, and pain. BMB-202's potential as a best-in-class treatment is highlighted, with optimized properties such as a short half-life and strong potency, outperforming psilocin in vitro. The CEO emphasized this as a crucial step in protecting their innovative compounds globally.